Literature DB >> 26139098

MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis.

Setareh Alampour-Rajabi1, Omar El Bounkari1, Antal Rot1, Gerhard Müller-Newen1, Françoise Bachelerie1, Meinrad Gawaz1, Christian Weber1, Andreas Schober1, Jürgen Bernhagen2.   

Abstract

Macrophage migration-inhibitory factor (MIF) is a pleiotropic cytokine with chemokine-like functions and is a mediator in numerous inflammatory conditions. Depending on the context, MIF signals through 1 or more of its receptors cluster of differentiation (CD)74, CXC-motif chemokine receptor (CXCR)2, and CXCR4. In addition, heteromeric receptor complexes have been identified. We characterized the atypical chemokine receptor CXCR7 as a novel receptor for MIF. MIF promoted human CXCR7 internalization up to 40%, peaking at 50-400 nM and 30 min, but CXCR7 internalization by MIF was not dependent on CXCR4. Yet, by coimmunoprecipitation, fluorescence microscopy, and a proximity ligation assay, CXCR7 was found to engage in MIF receptor complexes with CXCR4 and CD74, both after ectopic overexpression and in endogenous conditions in a human B-cell line. Receptor competition binding and coimmunoprecipitation studies combined with sulfo-SBED-biotin-transfer provided evidence for a direct interaction between MIF and CXCR7. Finally, we demonstrated MIF/CXCR7-mediated functional responses. Blockade of CXCR7 suppressed MIF-mediated ERK- and zeta-chain-associated protein kinase (ZAP)-70 activation (from 2.1- to 1.2-fold and from 2.5- to 1.6-fold, respectively) and fully abrogated primary murine B-cell chemotaxis triggered by MIF, but not by CXCL12. B cells from Cxcr7(-/-) mice exhibited an ablated transmigration response to MIF, indicating that CXCR7 is essential for MIF-promoted B-cell migration. Our findings provide biochemical and functional evidence that MIF is an alternative ligand of CXCR7 and suggest a functional role of the MIF-CXCR7 axis in B-lymphocyte migration. © FASEB.

Entities:  

Keywords:  CD74; chemokine; chemokine receptor; cytokine; receptor complex

Mesh:

Substances:

Year:  2015        PMID: 26139098     DOI: 10.1096/fj.15-273904

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  46 in total

1.  Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Authors:  Amanda Sparkes; Patrick De Baetselier; Lea Brys; Inês Cabrito; Yann G-J Sterckx; Steve Schoonooghe; Serge Muyldermans; Geert Raes; Richard Bucala; Peter Vanlandschoot; Jo A Van Ginderachter; Benoît Stijlemans
Journal:  FASEB J       Date:  2018-01-25       Impact factor: 5.191

Review 2.  New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Authors:  Andrew B Kleist; Anthony E Getschman; Joshua J Ziarek; Amanda M Nevins; Pierre-Arnaud Gauthier; Andy Chevigné; Martyna Szpakowska; Brian F Volkman
Journal:  Biochem Pharmacol       Date:  2016-04-19       Impact factor: 5.858

3.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 4.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

Review 5.  The non-mammalian MIF superfamily.

Authors:  Amanda Sparkes; Patrick De Baetselier; Kim Roelants; Carl De Trez; Stefan Magez; Jo A Van Ginderachter; Geert Raes; Richard Bucala; Benoît Stijlemans
Journal:  Immunobiology       Date:  2016-10-12       Impact factor: 3.144

6.  The IL-25-dependent tuft cell circuit driven by intestinal helminths requires macrophage migration inhibitory factor (MIF).

Authors:  Fumi Varyani; Stephan Löser; Kara J Filbey; Yvonne Harcus; Claire Drurey; Marta Campillo Poveda; Orhan Rasid; Madeleine P J White; Danielle J Smyth; François Gerbe; Philippe Jay; Rick M Maizels
Journal:  Mucosal Immunol       Date:  2022-03-14       Impact factor: 7.313

7.  Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74.

Authors:  Roberto Meza-Romero; Gil Benedek; Kelley Jordan; Lin Leng; Georgios Pantouris; Elias Lolis; Richard Bucala; Arthur A Vandenbark
Journal:  Cytokine       Date:  2016-08-27       Impact factor: 3.861

8.  Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.

Authors:  Corinna Schmitz; Heidi Noels; Omar El Bounkari; Eva Straussfeld; Remco T A Megens; Marieke Sternkopf; Setareh Alampour-Rajabi; Christine Krammer; Pathricia V Tilstam; Norbert Gerdes; Christina Bürger; Aphrodite Kapurniotu; Richard Bucala; Joachim Jankowski; Christian Weber; Jürgen Bernhagen
Journal:  FASEB J       Date:  2018-03-15       Impact factor: 5.191

Review 9.  Chemokines in Myocardial Infarction.

Authors:  Bijun Chen; Nikolaos G Frangogiannis
Journal:  J Cardiovasc Transl Res       Date:  2020-05-15       Impact factor: 4.132

10.  Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.

Authors:  Shahrzad Rafiei; Bin Gui; Jiaxin Wu; X Shirley Liu; Adam S Kibel; Li Jia
Journal:  Mol Cancer Res       Date:  2018-09-17       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.